EpiVax

Frontiers | A method for identifying neoantigens through isolation of circulating tumor cells using apheresis among patients with advanced-stage cancer BackgroundImmune checkpoint inhibitors show limited efficacy in tumors with low tumor mutational burden, partly due to insufficient neoantigen presentation.M...

Can circulating tumor cells replace tumor biopsies for neoantigen discovery?

This study explores a minimally invasive approach using apheresis, flow cytometry, and exome sequencing to identify neoantigens from CTCs in advanced-stage cancer patients.

More here:
www.frontiersin.org/journals/imm...

15.07.2025 13:31 — 👍 0    🔁 0    💬 0    📌 0

Postdoc Chad Brambley presenting at the AI/HI workshop.

The AI/HI workshop sponsored by Epivax.

Super postdoc @chadbrambley.bsky.social killing it at the AI/HI Immunoinformatics workshop, telling us about finding molecular mimics of antigenic epitopes. Thanks to @epivax.bsky.social for the invitation and opportunity!

06.06.2025 15:48 — 👍 7    🔁 1    💬 0    📌 1

T-cell responses to highly conserved SARS-CoV-2 epitopes in Hispanic Americans receiving an mRNA COVID-19 vaccine This study reports the pre-clinical evaluation of peptides from EPV-CoV-19, a T cell epitope-based SARS-CoV-2 vaccine candidate, following spike-mRNA vaccination of a predominantly Hispanic America...

The latest Epi-paper is out!

We studied a peptide-based COVID-19 booster in a mostly Hispanic American cohort to address gaps in representation. The findings support durable T cell immunity and a step toward greater health equity in vaccine research.

bit.ly/4mDCvv5

29.05.2025 14:53 — 👍 1    🔁 0    💬 0    📌 0

EpiVax Appoints Dr. Vibha Jawa to Lead Scientific Strategy as CSO - EpiVax EpiVax announces the appointment of Chief Scientific Officer (CSO), Vibha Jawa PhD, FAAPS to lead scientific strategy of the company.

We’re excited to finally share: Dr. Vibha Jawa is EpiVax’s new Chief Scientific Officer.

She’s a powerhouse in immunogenicity science with 20+ years of experience in biologics, vaccines, and gene therapy.

Big things ahead. Welcome, Vibha!

Full announcement: epivax.com/epivax-appoi...

28.05.2025 17:41 — 👍 2    🔁 0    💬 0    📌 0

Frontiers | Regulatory T cell epitope content in human antibodies decreases during maturation

As antibodies mature, they lose regulatory T cell epitopes while keeping effector signals. Read about our latest study for a new lens on immune tolerance, autoimmunity, and antibody design.

🧬 bit.ly/42G0voc

#immunology #antibodies

21.04.2025 15:22 — 👍 1    🔁 0    💬 0    📌 1

Immunogenicity of Generic Peptide Impurities: Current Orthogonal Approaches - Pharmaceutical Research Generic drugs have saved consumers billions of dollars in the United States. The demand for lower-cost and effective drugs, particularly for well-known peptide drugs like Ozempic and Wegovy (brand nam...

🚨 EpiVax has filed a Model Master File (MMF) for our PANDA® In Silico Model with the FDA, helping to streamline ANDA filings. Learn more about our approach to assessing the immunogenicity of generic peptide drugs in this new publication: 🔗 link.springer.com/article/10.1...

26.03.2025 14:01 — 👍 1    🔁 0    💬 0    📌 0